Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for DuoGenic StemCells's FCF Margin % or its related term are showing as below:
ROCO:7607'
s FCF Margin % Range Over the Past 10 Years
Min: -1262.52 Med: -402.72 Max: -89.28
Current: -89.28
During the past 5 years, the highest FCF Margin % of DuoGenic StemCells was -89.28%. The lowest was -1262.52%. And the median was -402.72%.
ROCO:7607's FCF Margin % is ranked worse than 51.16% of 950
companies
in the Biotechnology industry
Industry Median: -81.28
vs ROCO:7607: -89.28
DuoGenic StemCells FCF Margin % Related Terms
DuoGenic StemCells FCF Margin % Historical Data
* Premium members only.
The historical data trend for DuoGenic StemCells's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7607 vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, DuoGenic StemCells's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DuoGenic StemCells FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, DuoGenic StemCells's FCF Margin % distribution charts can be found below:
* The bar in red indicates where DuoGenic StemCells's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DuoGenic StemCells (ROCO:7607) has a FCF Margin % of -95.70% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DuoGenic StemCells and its competitors. According to the industry distribution chart, DuoGenic StemCells ranks #486 out of 950 companies in the Biotechnology industry, placing it in the top 51.2%.
Is DuoGenic StemCells' FCF Margin % too high?
DuoGenic StemCells' current FCF Margin % is -95.70%. Based on the distribution chart, DuoGenic StemCells ranks #486 out of 950 companies in the Biotechnology industry, which is below the industry midpoint. Overall, DuoGenic StemCells has a GF Score™ of 25/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DuoGenic StemCells' FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, DuoGenic StemCells ranks #486 out of 950 companies for FCF Margin %. This places DuoGenic StemCells in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on DuoGenic StemCells and its competitors. DuoGenic StemCells's current FCF Margin % is -95.70%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DuoGenic StemCells stock overvalued right now?
Based on GuruFocus' analysis, DuoGenic StemCells (ROCO:7607) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$51.22, compared to a current price of NT$13.00 — trading 74.6% below its estimated fair value. The current FCF Margin % is -95.70%. DuoGenic StemCells' overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For DuoGenic StemCells (ROCO:7607), the current FCF Margin % is -95.70% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DuoGenic StemCells (ROCO:7607) Overvalued in 2026?
Based on GuruFocus' analysis, DuoGenic StemCells stock appears to be undervalued.
The current stock price of NT$13.00 is trading 74.6% below its estimated GF Value™ of NT$51.22.
GuruFocus considers DuoGenic StemCells to be Significantly Undervalued.
Key valuation signals for ROCO:7607:
FCF Margin %: -95.70%
GF Value™: NT$51.22 vs. price of NT$13.00 (74.6% below fair value)
No single metric tells the full story. See the ROCO:7607 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DuoGenic StemCells Corp is a company having a team of passionate researchers focused on stem cell cultivation. Their products are intended for research use and can be upgraded for clinical applications. It also develops blood cell therapy programs, using the isolation and purification of blood mononuclear cells to remove granule cells that promote inflammation, and conducts clinical trials on various degenerative diseases to provide a convenient and simple new option for cell therapy.
25GF Score
Get the complete analysis for ROCO:7607
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7607 has been successfully added to your 
